Weizhou Zhang

34PUBLICATIONS
166CO-AUTHORS
Haematological tumoursNoise and wave pollution processes and measurementMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jul 30, 2026
PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.

|May 16, 2026
Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions.

|Apr 21, 2026
CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.

|Mar 14, 2026
Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.

Temitope M Ogunmola, Zeng Jin, Jeremy Kleberg

|Sep 13, 2025
Epithelial-Mesenchymal Transition Activates YAP to Drive Malignant Progression and Immune Evasion.

Xi Huang, Mingyan Zhang, Alexander D Pearce

|Sep 02, 2025
CerS2 is a druggable target in triple-negative breast cancer.

Hissah Alatawi, Haritha H Nair, Lingbao Ai

Pageof 6

Frequent Collaborators

9 joint publications

Chandra K Maharjan

6 joint publications

Guangrong Zheng

4 joint publications

Daohong Zhou

4 joint publications

Jeremy Kleberg